BioCentury | Sep 11, 2020
Product Development

ACTIV-4 trials to zero in on best agents and disease stages for addressing blood clots in COVID-19

...will receive low or high dose Eliquis apixaban...
...One-off Phenomenon Confined to COVID-19”). Sandi Wong Eliquis, apixaban (BMS-562247-01) NIH Neurology Cardiovascular Stroke Myocardial...
BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

...is limited to reversing the effects of the two best-selling oral Factor Xa inhibitors: Eliquis apixaban...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...agent is approved in the U.S. and EU to reverse the effects of anticoagulants Eliquis apixaban...
BioCentury | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

...to $39.4 billion, driven by sales of breast cancer drug Ibrance palbociclib, cardiovascular therapy Eliquis apixaban...
...targeted agents in the U.S. There are two other marketed CDK4/6 inhibitors in the U.S. Eliquis...
BioCentury | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

...by 7%, Bristol-Myers Squibb Co. (NYSE:BMY) increased the list price on its blood thinner Eliquis apixaban...
BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

...Pfizer Inc. (NYSE:PFE) had on sales of the anticoagulant Eliquis apixaban in China. Patents on Eliquis...
...May of 2019, respectively. "BMS owns a composition of matter patent in China that covers apixaban...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Time to fulfill China’s promise of IP reform

...approved generic drugs before the expiration of patents listed in China’s Orange Book protecting Eliquis apixaban...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Time to fulfill China’s promise of IP reform

...approved generic drugs before the expiration of patents listed in China’s Orange Book protecting Eliquis apixaban...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...NASDAQ:PTLA) EC conditionally approves Ondexxya andexanet alfa to reverse the effect of anticoagulant drugs Eliquis apixaban...
BioCentury | Apr 26, 2019
Company News

European regulatory roundup: CHMP opinions and a Portola approval

...andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse the effect of anticoagulant drugs Eliquis apixaban...
Items per page:
1 - 10 of 188